Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892333 | 0.88 | MEN1 (0.78) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL892401 | 0.87 | MEN1 (0.77) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5353245 | 0.83 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL799678 | 0.83 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891470 | 0.81 | MEN1 (0.73) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3739 | 0.81 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3270220 | 0.81 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL892439 | 0.80 | KMT2A (0.55) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.80 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.80 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | disclosed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TET1, SLC16A1, ADH1A | MEN1 222/4885PABPC1 4434/4885KMT2A 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.